Top

Published in:

01-04-2015 | Research

Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

Authors: Sabrina Zidi, Mouna Stayoussef, Ferjeni Zouidi, Samir Benali, Ezzedine Gazouani, Amel Mezlini, Besma Yacoubi-Loueslati

Published in: Pathology & Oncology Research | Issue 2/2015

Abstract

Host genetic factors may confer susceptibility to Cervical Cancer. TNF-α as pro-inflammatory cytokine participates in the maintenance of immune homeostasis. Allelic variation of immuno-modulatory genes is associated with alteration in immune function. This study investigated the associations between TNF-α-308G>A, −238G>A, and TNFRII - VNTR-322 and cervical cancer in Tunisian women. Genotypes of those polymorphisms were detected in 130 cases and 260 controls. The variant heterozygote −308 G/A was associated with a 41 % decreased risk of cervical cancer (GG vs A/A; p = 0.002; OR = 0.41; 95 % CI =0.23–0.76). Furthermore, compared with dominant variant G/G, the (G/A+A/A) genotypes was significantly associated with a decreased risk of CC (GG vs G/A+A/A; p = 0.026; OR = 0.62; 95 % CI = 0.40–0.97). The FIGO stratified analysis showed that the minor variant A/A and combined G/A+A/A of TNFα-238 G>A and TNFα-308 G>A increased the risk of the tumor evolution, respectively, (P = 0.011; OR = 2.98; 95 % CI = 1.16–7.72) (P = 0.008; OR = 2.76; 95 % CI = 1.20–6.41), (P = 0.000; OR = 16.33; 95 % CI = (5.10–55.23) (P = 0.000; OR = 7.54; 95 % CI = 2.68–22.29). There was statistically significant relationship between the incidence of the TNF-α mutations and the clinical progression of cancer according to the FIGO classification. In our study, the haploview analysis revealed no LD between rs1800629 and rs361525. TNF-α and TNFRII polymorphisms might be genetic risk factors for cervical cancer inTunisian population

Ahmed MI, Salahy EE, Fayed ST et al (2001) Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha. Clin Biochem 34(6):491–498CrossRefPubMed

Allendoerfer R, Magee DM, Smith JG et al (1993) Induction of tumor necrosis factor-α in murine Candida albicans infection. Oxf J Med J Infect Dis 167(5):1168–1172CrossRef

Ardizzoia A, Lissoni P, Brivio F et al (1992) Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6(3):103–107PubMed

Asghar T, Yoshida S, Kennedy S et al (2004) The tumor necrosis factor-apromoter 1031C polymorphism is associated with decreased risk of endometriosis in a Japanese population. Hum Reprod 19:2509–2514CrossRefPubMed

Aukrust P, Sandberg WJ, Otterdal K et al (2011) Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med 43:90–103CrossRefPubMed

Badano I, Stietz SM, Schurr TG et al (2012) Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol 53:54–59CrossRefPubMed

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow. Lancet 17:539–545

Barbisan G, Perez LO, Contreras A et al (2012) TNF-alpha and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33:1549–1556CrossRefPubMed

Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717CrossRefPubMed

10.

Bernard HU, Burk RD, Chen Z et al (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70–79CrossRefPubMedCentralPubMed

11.

Burkly LC, Michaelson JS, Zheng TS (2011) TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 244:99–114CrossRefPubMed

12.

Calhoun ES, Mcgovern RM, Janney CA et al (2002) Host genetic polymorphism analysis in cervical cancer. Clin Chem 48(8):1218–1224PubMed

13.

Chopra V, Dinh TV, Hannigan EV (1998) Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Investig 16:152–159CrossRef

14.

Craveiro R, Costa S, Pinto D et al (2004) TP73 alterations in cervical carcinoma. Cancer Genet Cytogenet 150:116–121CrossRefPubMed

15.

De Freitas AC, Gurgel AP, Chagas BS et al (2012) Susceptibility to cervical cancer: an overview. Gynecol Oncol 126:304–311CrossRefPubMed

16.

De Giovine FS, Camp NJ, Cox A et al (2000) Detection and population analysis of IL-1 and 430 TNF gene polymorphisms in cytokine molecular biology. Oxford University, Oxford, pp 21–46

17.

Deshpande A, Nolan JP, White PS et al (2005) TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 191(6):969–976CrossRefPubMed

18.

Ding B, Shilong F, Meilin W et al (2012) Tumor Necrosis Factor α −308 G>A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer 22(2):213–219CrossRefPubMed

19.

Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11–22CrossRefPubMed

20.

Duarte I, Santos A, Sousa H et al (2005) G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334:588–592CrossRefPubMed

21.

Fong CL, Siddiqui AH, Mark DF (1994) Identification and characterization of a novel repressor site in the human tumor necrosis factor ogene. Nucleic Acids Res 22(6):1108–1114CrossRefPubMedCentralPubMed

22.

Gostout BS, Poland GA, Calhoun ES et al (2003) TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 88:326–323CrossRefPubMed

23.

Govan VA, Constant D, Hoffman M et al (2006) The allelic distribution of −308 tumor necrosis factor-alpha gene polymorphism in south African women with cervical cancer and control women. BMC Cancer 6:24CrossRefPubMedCentralPubMed

24.

Hallermalm K, Seki K, Wei CH et al (2001) Tumor necrosis factor–a induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 98:1108–1115CrossRefPubMed

25.

Ibeanu OA (2011) Molecular pathogenesis of cervical cancer. Cancer Biol Ther 11:295–306CrossRefPubMed

26.

Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor a: prevalence to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233

27.

Jang WH, Yang YI, Yea SS et al (2001) The −238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 166(1):41–46CrossRefPubMed

28.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed

29.

Keen L, Wood N, Olomolaiye O et al (1999) A bi-allelic VNTR in the human TNFR2 (p75) gene promoter. Genes Immunol 1:164CrossRef

30.

Kohaar I, Thakur N, Salhan S et al (2007) TNFalpha-308 G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol 29:249–256PubMed

31.

Liu L, Yang X, Chen X et al (2012) Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep 39:2683–2689CrossRefPubMed

32.

Ljunggren G, Anderson DJ (1998) Cytokine-induced modulation of MHC class-I and class-II molecules on human cervical epithelial cells. J Reprod Immunol 38:123–138CrossRefPubMed

33.

Mekinian A, Tamouza R, Pavy S et al (2011) Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw 22:88–102PubMed

34.

Naylor MS, Stamp GW, Foulkes WD et al (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91:2194–2206CrossRefPubMedCentralPubMed

35.

Pan F, Tian J, Ji C-S et al (2012) Association of TNF-α-308 and-238 polymorphisms with risk of cervical cancer: a meta-analysis. Asian Pac J Cancer Prev 13(11):5777–5783

36.

Patel R, Cafardi JM, Patel N et al (2011) Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther 11:1341–1359CrossRefPubMed

37.

Perrey C, Turner SJ, Pravica V et al (1999) ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms. Transpl Immunol 7:127–128CrossRefPubMed

38.

Qidwai T, Khan F (2011) Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 74:522–547CrossRefPubMed

39.

Santos AM, Sousa H, Catarino R et al (2005) TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. Cancer Genet Cytogenet 159:143–147CrossRefPubMed

40.

Shepperd JH (1995) FIGO staging of gynecologic cancers; cervical and vulva. Int J Gynecol Cancer 5:319–323

41.

Shishodia S, Majumdar S, Banerjee S et al (2003) Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosporylation: Correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res 63:4375–4383PubMed

42.

Stanczuk GA, Sibanda EN, Tswana SA et al (2003) Polymorphism at the −308-promoter position of the tumor necrosis factoralpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer 13:148–153CrossRefPubMed

43.

Steinshamn S, Bemelmans MH, Van Tits LJ et al (1996) TNF receptors in murine Candida Albicans infection: evidence for an important role of TNF receptor p55 in antifungal defence. J Immunol 157:2155PubMed

44.

Thomas M, Narayan N, Pim D et al (2008) Human papillomaviruses, cervical cancer and cell polarity. Oncogene 27:7018–7030CrossRefPubMed

45.

Upasna G, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66(8):1403–1408CrossRef

46.

Van Heel DA, Udalova IA, De Silva AP et al (2002) Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum Mol Genet 11:1281–1289CrossRefPubMed

47.

Wang N, Yin D, Zhang S et al (2012) TNFalpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population. PLoS One 7:e45246CrossRefPubMedCentralPubMed

48.

Wang SS, Bratti MC, Rodriguez AC et al (2009) Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 199:20–30CrossRefPubMedCentralPubMed

49.

Wilson AG, De Giovine FS, Duff GW (1995) Genetics of TNF-α in autoimmune, infectious and neoplastic diseases. J Inflamm 45:1PubMed

50.

Wilson AG, Symons JA, McDowell TL et al (1997) Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci U S A 94:3195–3199CrossRefPubMedCentralPubMed

51.

Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7:411–425CrossRefPubMedCentralPubMed

52.

Zhang H-L, Zhang Y-J (2013) A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumor Biol 34(3):1659–1665

53.

Zidi S, Verdi H, Yilmaz-Yalcin Y et al (2014) Impact of Toll-Like Receptors 2/3/4/9, IL-1-a/b and TNF-a Polymorphisms in Cervical Cancer Susceptibility in Tunisia Pathol Oncol Res doi:10.1007/s12253-014-9793-7.

54.

Zuo F, Liang W, Ouyang Y et al (2010) Association of TNF-α gene promoterpoly-morphisms with susceptibility of cervical cancer in Southwest China. Lab Med 42:287–290

Title: Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians
Authors: Sabrina Zidi
Mouna Stayoussef
Ferjeni Zouidi
Samir Benali
Ezzedine Gazouani
Amel Mezlini
Besma Yacoubi-Loueslati
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9826-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms

Overexpression of Autophagy-Related 16-Like 1 in Patients with Oral Squamous Cell Carcinoma

Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma

Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer

Notch Signaling Target Genes are Directly Correlated to Esophageal Squamous Cell Carcinoma Tumorigenesis

Lantana camara Induces Apoptosis by Bcl-2 Family and Caspases Activation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer